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Abstract
The GATA family of transcription factors are zinc finger (ZF) DNA-binding pro-
teins that regulate transcription during development and cell differentiation.
GATA2 plays an essential role in the regulation of hematopoiesis. As a result,
mutations in this gene or alterations in its expression level or function have been
linked to a variety of human hematologic disorders. In this review, we summarize
the findings and developments over the recent years regarding the clinical correla-
tions and functional properties of distinct GATA2 mutations in hematopoietic
malignancies, with particular focus on the mutational hotspots in the ZF domains.
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1 | INTRODUCTION
GATA binding protein 2 (GATA2) belongs to the
GATA family of transcription factors that regulate
hematopoietic stem cell self-renewal and differentia-
tion.1 GATA2 is crucial for the proliferation and main-
tenance of hematopoietic stem cells and multipotent
progenitors and plays important roles in the develop-
ment of eukaryotic organisms.2 The name of the
gene is derived from the ability of its protein product
to bind the consensus DNA sequence (A/T)GATA
(A/G) through two highly conserved zinc finger
(ZF) domains.3 Both somatic and hereditary GATA2
mutations have been reported in myeloid neoplas-
ia, including chronic myeloid leukemia (CML), myelo-
dysplastic syndrome (MDS)/acute myeloid leukemia
(AML).4–7 The incidence of GATA2 mutation in AML
varies depending on the patient cohort and disease
subtype considered.8–10
Germline GATA2 mutations underlie an autosomal
dominant predisposition to early onset MDS/AML often
with an aggressive disease course and poor outcome.4
Accordingly, constitutional GATA2 alterations were
recently reported in pediatric MDS frequently rep-
resenting de novo germline events.5 Heterozygous path-
ogenic germline GATA2 mutations also cause a
complex immunodeficiency disorder with variable
degree of multilineage cytopenias and different clinical
manifestations. Initially, they were identified as differ-
ent entities, like Monocytopenia and mycobacterial
infection syndrome, Dendritic cell, monocyte, B and
NK lymphoid deficiency (DCML), and Emberger
syndrome,6,11,12 and are now referred to as GATA2 defi-
ciency.13 Patients with GATA2 deficiency have an
Abbreviations: AEL, Acute erythroid leukemia; AML, Acute myeloid
leukemia; ATRA, All-trans-retinoic acid; CEBPA, CCAAT/enhancer-
binding protein alpha; CFU-G, Colony forming unit granulocyte; CFU-M,
Colony forming unit monocyte; CML, Chronic myeloid leukemia; DCML,
Dendritic cell, monocyte, B and NK lymphoid; del, Deletion; DFS, Disease-
free survival; EFS, Event-free survival; FAB, French-American-British;
GATA2, GATA-binding factor 2; GOF, Gain of function; inv, Inversion;
LOF, Loss of function; MDS, Myelodysplastic syndrome; MonoMAC,
Monocytopenia and mycobacterial infection; OS, Overall survival; RFS,
Relapse-free survival; t, Translocation; WT, Wild-type; ZF, Zinc finger.
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increased propensity to develop MDS/AML, which,
among other explanations, may arise due to the
impaired immune capacity and bone marrow stress.
Nevertheless, pediatric patients with germline GATA2
mutation can present MDS without a recognized immu-
nodeficiency.5,14 On a functional level, these mutations
often possess compromised transcriptional activity and
may have dominant-negative characteristics.15 GATA2
germline mutations predominately cause amino acid
substitutions in the C-terminal ZF2-domain or trunca-
tions throughout the protein.
Somatic GATA2 mutations mainly cluster in the
two ZF domains and are associated with specific leu-
kemia subtypes, like CML progression to blast crisis,
or AML with CCAAT/enhancer-binding protein alpha
(CEBPA) mutations.8,16 Phenotypic correlations and
defined mutational clustering distinguish ZF1 and ZF2
GATA2 mutations, indicating that they may represent
fundamentally different leukemogenic mechanisms.17
In this review, we summarize the current understand-
ing and controversies of GATA2 ZF mutations in the
context of their clinical correlations and functional
consequences.
2 | GATA2 ZF MUTATIONS:
INCIDENCE AND CLINICAL
CORRELATIONS IN
HEMATOLOGICAL MALIGNANCIES
Zhang et al. identified the somatic ZF2 mutation L359V in
CML patients with blast crisis (Figure 1). They described
L359V to be a gain-of-function (GOF) mutation, which led
to enhanced DNA binding and coactivator recruitment
when compared to GATA2 wild-type (WT).18 In a subse-
quent publication, the group also confirmed that this
mutation is exclusively associated with CML progression
but not with other hematological malignancies.16 Because
of the unfavorable outcome of patients with the GATA2
L359V mutation, they suggested that this mutation might
also serve as adverse prognostic marker.16,18 A summary
of the discussed articles is provided in Table 1.
Hahn et al. described the germline ZF2 mutant
T354M, as loss-of-function (LOF) mutation, which corre-
lates with an early onset MDS/AML. T354M mutations in
GATA2 were not found in a cohort of sporadic AML
patients, although they could not completely rule out
possible mutations due to the presence of samples with
AML
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FIGURE 1 Schematic
representation of mutation hotspots in
the ZF region of GATA2. Only missense
mutations occurring in the same
position in three or more patients with
myeloid malignancies are represented.
Data from the Catalogue of Somatic
Mutations in Cancer (COSMIC v90).
AML, acute myeloid leukemia; CML,
chronic myeloid leukemia; MDS,
myelodysplastic syndrome; NLS, nuclear
localization sequence; NRD, negative
regulatory domain; TAD, transactivation
domain, ZF1, zinc finger 1; ZF2, zinc
finger 2
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low percentage blasts. Additionally, they analyzed global
gene expression and observed that the T354M mutation
lead to a complete LOF while L359V led to a GOF and
partial loss (1,253 newly regulated and 457 no longer reg-
ulated genes) when compared to GATA2 WT.4
Interestingly, Dickinson et al. described disruptive
germline mutations in GATA2 ZF2 (including T354M
and R398W) as the cause for DCML, which predisposed
to myelodysplasia and leukemia.12
Chong et al. reported recurrent germline ZF2 muta-
tions. T354M, R396Q, and R398W, which all predisposed
to myeloid malignancies, with different phenotypical
tendencies (T354M: MDS/AML; R396Q: immunodefi-
ciency; R398W: MonoMAC syndrome) and showed no
difference in leukemia-free survival of the affected
patients. In their study, they concluded that variable
DNA-binding affinity alone was not enough to explain an
association between specific ZF2 mutations and hemato-
logical malignancy subtypes. The authors summarized
that, although those ZF2 mutations broadly predispose to
MDS/AML, they appeared to confer unique characteris-
tics regarding differential GATA2 DNA-binding affinity,
protein–protein interactions, transactivation potential,
colony formation, and differentiation. These results may
TABLE 1 Summary of the clinical data of the cited studies
Publication Cohort and patient number Key finding
Zhang et al.,18 85 unselected CML patients with blast
transformation
L359V: GOF, exclusively associated with CML,
adverse prognostic marker
Dickinson et al.12 Four unrelated patients with MonoMAC GATA2 ZF2 mutations cause MonoMAC syndrome
Hahn et al.4 Five four pedigrees with predisposition to
MDS/AML, prescreened for absence of RUNX1 or
CEBPA germline mutations
T354M: LOF, associated with early onset of
MDS/AML
Yan et al.10 Nine paired samples of AML-M5 cases Found P304H, C319S, and R362Q
Fasan et al.9 98 cases of GATA2 mutations in intermediate-risk
karyotype AML with biallelic CEBPA mutations
GATA2 mutations in biCEBPA and association
with female sex and favorable survival
Greif et al.8 160 adult AML patients with a normal karyotype
(diagnostic bone marrow or peripheral blood
samples)
Recurrent GATA2 ZF1 mutations associated
exclusively with biCEBPA mutations in AML
Green et al.19 153 sporadic AML patients, 3 members of a germline
CEBPA-mutant family
GATA2 mutation do not impact favorable outcome
of biCEBPA patients
Hou et al.20 192 adult patients who were newly diagnosed as
having de novo AML
GATA2 mutations second hit, FAB M1 and M4,
better OS and RFS
Gröschel et al.21 32 AML (including 2 cell lines MUTZ-3 and UCSD-
AML1), 4 CML-BC (including 2 cell lines HNT-34
and MOLM-1), and 5 MDS cases
Negative correlation with RUNX1 mutations, co-
occurrence with SF3B1 mutations, most
commonly mutated transcription factor in inv(3)/
t(3;3)
West et al.22 48 patients with GATA2 deficiency 29% had ASXL1 mutations with earlier onset of
myeloid transformation
Theis et al.23 202 AML patients with CEBPA single or CEBPA
double mutations
GATA2 mutations in moCEBPA, no impact on
outcome
Ping et al.24 158 AEL patients ZF1 mutations in AEL
Chong et al.15 98 patients (clinical information correlated with
common germline GATA2 mutations from)
gathered in studies from 27 confirmed kindreds
and 7 individuals with de novo mutations
T354M, R396Q, and R398W show no difference in
leukemia-free survival
Al Seraihi et al.25 Five-generation family with GATA2 T354M
MDS/AML
GATA2–ASXL1 mutation insufficient for leukemia,
allele-specific expression of mutant allele
Tien et al.17 693 newly diagnosed de novo non-M3 AML L359V in BCR-ABL negative AML, longer OS,
better DFS, acquired ZF1 mutations at relapse
Note: Pubmed search criteria: GATA2, leukemia, ZF, hematopoiesis, AML, and CML.
Abbreviations: AML, acute myeloid leukemia; CML, chronic myeloid leukemia; DFS, disease-free survival; GOF, gain of function; LOF, loss of function; MDS,
myelodysplastic syndrome; OS, overall survival; RFS, relapse-free survival; ZF1, zinc finger 1; ZF2, zinc finger 2.
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explain the differences in age of onset and disease sub-
types described by the authors.15
Greif et al. found a specific association of biallelic
CEBPA mutations in cytogenetically normal AML with
recurrent somatic mutations in the ZF1 of GATA2. In
this study, the authors did not observe any significant
difference in clinical parameters, like age or sex,
between biallelic CEBPA-mutated patients with and
without mutations in GATA2. The presence of GATA2
mutations did not negatively affect the favorable overall
survival (OS) and event-free survival (EFS) of biallelic
CEBPA patients but there was a trend toward a better
OS and EFS for biallelic CEBPA patients with addi-
tional GATA2 mutations. This study shows that GATA2
mutations were mutually exclusive with NPM1 muta-
tions suggesting alternative mechanisms of leukemogen-
esis. Moreover, GATA2 mutations led to a reduction of
transcription of CEBPA target genes, pointing toward
an oncogenic cooperativity.8 They also showed that
there were genes enriched in the GATA2-mutated sub-
group being MYC, JUNB, FOS, and CEBPB among
others.8
The striking association of somatic GATA2 muta-
tions with biallelic CEBPA mutations was confirmed by
Fasan et al. in a large set of intermediate-risk AML
patients. In addition, they provided data on GATA2
mutations in CEBPA WT AML at a frequency of 3.3%.
The group demonstrated that GATA2 mutations were
secondary events, were associated with female sex, and
had a favorable impact on clinical outcome.9 In con-
trast, Green et al. showed that GATA2 mutation does
not impact the favorable outcome of biallelic CEBPA-
mutated patients.19
Hou et al. observed that in all patients with somatic
GATA2 mutations, there were concurrent mutations of
other genes, mostly CEBPA. Additionally, they showed
that the mutations might be lost or gained during dis-
ease progression. In their cohort, the mutations were
closely associated with younger age and FAB M1 sub-
type but were mutually exclusive with NPM1 mutation
and FAB M4 subtype. In their study, mutations in
GATA2 correlated with better OS and relapse-free sur-
vival (RFS).20
Theis et al. confirmed a high incidence of somatic
GATA2 mutations in the subgroup of patients with
biallelic CEBPA mutations. Moreover, the authors also
detected GATA2 mutations in AML with monoallelic
CEBPA mutations at a low frequency. In their study,
mutations in GATA2 did not impact clinical outcome,
neither in the overall AML patient cohort nor in distinct
patient subgroups. Therefore, they stated that the muta-
tional GATA2 status does not allow to further refine risk
stratification of this disease category.23
In a study by Gröschel et al., GATA2 was the most
commonly mutated transcription factor in inv(3)/t(3;3)
myeloid malignancies with 15% prevalence and all
occurred in ZF1 or ZF2. Furthermore, GATA2 muta-
tions were negatively correlated with RUNX1 muta-
tions, but enriched in samples with SF3B1 mutations.
All mutations found in that study were confirmed to be
somatic.21
Ping et al. identified somatic GATA2 mutations in
acute erythroid leukemia (AEL) patients. Most of the
observed mutations were missense and among them,
9 out of 12 were located in ZF1. They detected GATA2
mutations in 5.5% of non-AEL AML and in 15% of CML
in blast crisis and reported that the frequency of GATA2
mutations in AEL (22.4%) is significantly higher than in
non-AEL AML.24 Iacobucci et al. confirmed that these
data with a cohort of 159 child and adult AEL cases pre-
senting a mutational prevalence of 14.4%.26
Tien et al. analyzed GATA2 mutations in non-M3
AML patients and identified 44 GATA2 mutations in
43 (6.2%) of their 693 patients, two-thirds of those muta-
tions located in the ZF1 domain. In their cohort, ZF1
mutations were closely associated with FAB M1 subtype
and biallelic CEBPA mutations but not associated with
FAB M4 subtype, NPM1 mutations and FLT3-ITD. They
found that AML patients with ZF1 mutations had a sig-
nificantly longer OS than patients with GATA2 WT or
ZF2 mutations. ZF1 mutations also predicted better
disease-free survival (DFS) and a trend for better OS in
patients with biallelic CEBPA mutations. Consistent with
the previous studies of adult AML, GATA2 mutations
localized predominantly in the ZF1 region. In addition,
the authors reported two novel AML missense somatic
mutations, one of them being the ZF2 mutant L359V,
and that some patients acquired GATA2 ZF1 mutations
at relapse being R307L, G320D, L321P, and L321H.17
West et al. proposed that somatic alteration of
ASXL1 on the ground of GATA2 germline mutation is a
mechanism driving the onset and severity of disease
symptoms.22 In a subsequent study, Seraihi et al.
suggested that a combination of GATA2 and ASXL1
mutation alone is not sufficient to promote clonal
expansion and leukemic transformation, as this second-
ary somatic hit may not reliably represent disease pro-
gression or identify when treatment is indicated. They
did not detect other acquired mutations in the 33 mye-
loid genes assessed in their affected individuals. The
authors proposed allele-specific expression of the
GATA2 mutant allele as an alternative leukemogenic
mechanism. Moreover, they suggested that monosomy
7 may be acquired following the acquisition of ASXL1
mutations, therefore contributing to the malignancy but
not initiating symptoms.25
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3 | GATA2 ZF MUTATIONS:
FUNCTIONAL IMPLICATIONS
Zhang et al. reported that GATA2 L359V ZF2 somatic
mutant exhibited a higher transactivation potential, com-
pared to GATA2 WT and therefore suggested that L359V is
a GOF mutation. Hence, they claimed that GATA2 L359V
may recruit coactivators more effectively, thus resulting in
an increased transactivation of its target genes. Moreover,
they showed that GATA2 L359V presents an enhanced
binding to PU.1. Additionally, they observed that at the cel-
lular level, GATA2 mutations disturbed all-trans-retinoic
acid (ATRA)-induced differentiation of HL60 cells, which
would be a scenario similar to the block of differentiation
in blast cells. Therefore, they stated that the GOF of
GATA2 L359V may underline the blast crisis with the
myelomonocytic phenotype observed in CML patients.16,18
Hahn et al. observed that the germline GATA2 ZF2
mutation T354M dramatically reduced the ability of
GATA2 to bind its consensus DNA motif. Using Luciferase
reporter assays in HEK 293T cells, they showed that
T354M had significantly reduced transactivation ability
compared to WT on known GATA2 responsive enhancer
elements of RUNX1, CD34, and the LYL1 promoter.
Although the transcription assay in HEK 293T is rather
artificial, this model has been frequently used and yielded
conclusive data in the study of transcription factors.4,8,27
Under nondifferentiating conditions, they found that
T354M acted as LOF mutant unlike WT and L359V, which
inhibited proliferation and promoted apoptosis. However,
they also observed that in the presence of ATRA, T354M
alone enabled HL60 cell proliferation and survival while
simultaneously inhibiting differentiation and apoptosis.4
In a study of Chong et al., the group tested several
somatic and germline mutants. They showed different
DNA-binding capabilities: L359V displayed no significant
reduction in binding, in contrast to T354M, R362Q,
R398W, and the ZF1 mutant L321F that showed reduced
but still detectable binding. The mutants T355del, R361L,
C373R, and R396Q displayed little or no detectable bind-
ing. They reported that all mutants displayed a reduced
capability to transactivate transcription from at least one
GATA2-responsive element compared to WT. L359V dis-
played activity similar to WT or a mild GOF. The
mutants with the lowest DNA-binding affinity (T355del,
R361L and C373R) showed the most prominent reduc-
tion in transactivation, including complete abrogation in
some instances, whereas the mutants T354M, R362Q,
R398W, and L321F displayed residual transactivation
potential. Furthermore, they observed that all GATA2
mutants, except for L359V, showed reduced synergistic
transactivation with PU.1. Interestingly, T354 M and
C373R showed enhanced affinity to PU.1. Based on those
findings, the group claimed that despite transactivation
via GATA2-responsive elements was seen to correlate
with DNA-binding activity, the interaction and
coactivation with PU.1 varied between the tested
mutants. The group observed a striking derepression of
colony formation for most of the mutants. In the case of
L359V, the described de-repression of colony-forming
ability could not be explained by its effect on DNA bind-
ing and transactivation ability. Due to these findings, the
group suggested that there are both DNA-dependent and
independent effects of GATA2 mutations on differentia-
tion. In that study, T354M, L359V, and R362Q but not
others were able to repress colony forming unit monocyte
differentiation.15
Greif et al. observed that the ZF1 somatic mutants
A318T and L321F showed a reduced transactivation upon
cotransfection with a GATA-responsive reporter. The
G320D mutant showed an increased activation, whereas
the L359V mutant did not show a significant difference
when compared to GATA2 WT. In coimmunoprecipitation
experiments, the GATA2 mutants A318T, G320D, L321F,
and L359V were still able to interact with CEBPA
WT. CEBPA-dependent activation was enhanced by the
coexpression of GATA2 WT, but this enhancement was
reduced for all the GATA2 ZF1 mutants associated with
AML with biallelic CEBPA mutations, but not for the
CML-associated L359V mutant.8
Another study by Cortés-Lavaud et al. reported that
the GATA2 ZF2 germline mutations T354M, T355del,
and R396Q impair the transcriptional activity of GATA2.
The group furthermore described R396Q to be a LOF
mutation due to its abrogation in promoter binding, loss
of DNA binding ability and inability to retain a progeni-
tor phenotype. They found that R396Q increased the pro-
portion of colony forming unit granulocyte.28
Ping et al. showed that upon coexpression of GATA2
WT with the ZF1 somatic mutant R330X, the transcrip-
tional activity of GATA2 WT was significantly affected
and therefore concluded that R330X had a dominant-
negative effect over GATA2 WT. The authors did not
observe such a dominant-negative effect in ZF1 mutants
P304H and L321P. Additionally, in their study, the over-
expression of GATA2 mutants in the mouse myeloid pro-
genitor cell line 32D had no effect on proliferation or
colony-forming ability.24
Katsumura et al. analyzed the functional conse-
quences of GATA2 ZF1 somatic mutations from AML
patients in a mouse aortic endothelial cell assay. They
showed that while GATA2 WT activated specific target
genes, ZF1 leukemia mutations impaired the transcrip-
tional response. Using a genetic complementation assay,
they discovered that the GATA2 ZF1 mutant R307W,
which was predicted to be inactive or to have diminished
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activity, retained activity in primary cells. Of particular
interest to the group was its capacity to induce granulo-
cytic differentiation and cell cycle progression, which
they showed to exceed that of GATA2 WT. In their study,
they were able to highlight several functional differences
between ZF mutants: Although ZF1 mutations resembled
the effect of ZF2 mutations with respect to the disruption
of chromatin binding and target gene activation; ZF1
mutants were more efficient to activate target genes.29
4 | DISCUSSION AND
CONCLUSIONS
Germline mutations in GATA2 are either missense in the
ZF2, frameshift or stop spread across the gene. Generally,
they are associated with reduced DNA binding ability and
transactivation potential, consistent with a LOF pheno-
type.4,15 Of note, the only reported missense ZF1 germline
mutation affects a cysteine, which likely critically disrupts
the ZF structure, resulting in a complete LOF.5 The lack of
germline mutations in ZF1 can be explained by the
assumption that ZF1 mutations may be embryonic lethal.
Another possible explanation could be that ZF1 mutations
can only contribute to leukemogenesis on the specific
transcriptional context of cells with CEBPA deficiency.
The link between GATA2 germline mutations and higher
MDS/AML incidence is a well-established fact.4 These
patients present a high proportion of ASXL1 mutations,
monosomy 7 and trisomy 8,22,25 which suggest that
GATA2 mutation provides a specific fertile ground which
selects for these lesions (Figure 2, left panel). Based on the
existing literature it remains controversial if SETBP1
mutations are associated with GATA2 related MDS30 or
are rather associated with monosomy 7.31
Somatic GATA2 mutations show overall reduced
transactivation potential with a few exceptions8,24,29 and
skew the differentiation of hematologic progenitors
towards the granulocytic linage.29 So far, somatic muta-
tions in GATA2 ZF1 have been shown to co-occur with
mutations in CEBPA and SF3B1, FAB M1 subtype, AEL
and t(3;3) AML and to be mutually exclusive with
mutations in NPM1, RUNX1, and FLT3-ITD and FAB
M4 AML.8,17,21,24 The L359V mutant was earlier
described to be exclusively associated with CML,16
whereas more recent studies show an association with
BCR-ABL-negative AML.17 The prognostic value of
somatic GATA2 mutations remains controversial. The
discrepancies between the aforementioned studies may
arise from confounders such as the higher prevalence
of GATA2 mutation in females, patient age and the
favorable prognostic of CEBPA double mutations.9
Beyond AML with biallelic CEBPA mutations, we and
others recently found GATA2 mutations in t(8;21)
AML.32–34 In fact, AML1-ETO represses CEBPA
transcription,35 indicating that GATA2 mutations arise
on the fertile ground of CEBPA deficiency—due to
either CEBPA mutation or downregulation (Figure 2,
right panel). Another example for this correlation is
AML with 3(q21;q26) aberrations,21 where the over-
expression of EVI1 (MECOM) represses CEBPA,36 thus
providing the basis for acquisition of GATA2 mutations.
Additionally, somatic GATA2 mutations are either lost
or acquired as the disease progresses.20 The fact that
somatic GATA2 mutations frequently arise during AML
relapse suggests a role of GATA2 in chemotherapy
resistance.17
Another layer of complexity when navigating the
existent GATA2 mutational data is the fact that some
reported somatic mutations have not been tested for
germline status. This may result in typical GATA2
germline mutations, for example T354M, being reported
as somatic without assurance that those patients did not
have a germline mutation.
FIGURE 2 Evolutionary
patterns of GATA2 mutations in
myeloid leukemia. Left panel:
GATA2 germline mutation
provides a fertile ground for the
appearance of ASXL1 mutation,
monosomy of chromosome
7 and trisomy of chromosome
8. Right panel: CEBPA
deficiency provides a fertile
ground for the emergence of
GATA2 somatic mutations
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Although GATA2 has been in the spotlight of hemato-
logical research for several years, the exact mechanism of
leukemic promotion through GATA2 mutation remains
elusive. To date, it is clear that mutations in ZF1 and ZF2
have different functional consequences and co-occur with
specific leukemic lesions. The collaboration of GATA2
mutations with these lesions is likely to be the missing
piece in this puzzle. We can expect a much greater under-
standing of the prognostic value of these mutations as
patient cohorts expand, as well as a better functional
characterization as more specific leukemia models are
developed in the years to come.
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